Telmisartan plus chemo for platinum-resistant ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests adding telmisartan (a blood pressure medicine) to standard chemotherapy for people with ovarian cancer that no longer responds to platinum-based drugs. The goal is to see if the combination can help control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of ovarian cancer called high-grade serous carcinoma.
- Your cancer did not respond to or stopped responding to platinum chemotherapy.
- You are able to get around and take care of yourself (ECOG score 0, 1, or 2).
- Your liver, kidney, and blood cell counts are within safe levels (tests will check this).
- You are not taking certain blood pressure medicines or receiving bevacizumab as part of your current chemo.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a common cholesterol medicine (atorvastatin) to standard chemotherapy for advanced ovarian cancer. The goal is to see if the combination can help your immune system fight the cancer better.
This trial tests a new drug combination (trastuzumab rezetecan plus carboplatin) with or without bevacizumab, compared to standard chemotherapy, for ovarian cancer that has come back after platinum-based treatment. It aims to see if this combination works better than the usual options.
This trial tests adding a new drug, ubamatamab, to standard chemotherapy for advanced ovarian cancer that did not respond well to initial treatment. The goal is to see if this combination is safe and effective.
This trial tests a different way of giving chemotherapy to people with advanced ovarian cancer that didn't respond well to initial treatment. The goal is to see if changing the dose and schedule can improve outcomes.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This Phase 2 study tests adding mirvetuximab to carboplatin for people with advanced, high-grade serous ovarian cancer who will first receive “neoadjuvant” chemotherapy. It is designed for tumors that strongly show FRα, which mirvetuximab targets, to see if this improves outcomes.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.